Recently published data suggest that the addition of LPT to ipilimumab is safe and effective in patients with metastatic melanoma irrespective of clinical disease characteristics and known risk factors.
There are three different ways of knowing what current UV radiation levels are in New Zealand, where levels are monitored and measured by NIWA.
An international review involving University of Otago experts concludes that multicomponent community-wide interventions are effective in reducing the deleterious effects of UV exposure by increasing sunscreen use.
A large German registry-based study provides no evidence that people born in spring carry a higher risk for developing melanoma in later life and thus lends no support to the hypothesis of higher UVR susceptibility during the first months of life.
Study results suggest that Asian Australians are at risk of skin cancer, with over 35 % of the sample reported engaging in outdoor tanning and over 10 % in solarium tanning.
This series supports use of RT to limited sites of progression following ipilimumab as an alternative to other systemic treatments such as anti-programmed death-1 antibodies.
Use of SPF ≥ 15 rather than SPF < 15 sunscreens reduce melanoma risk, according to a population-based cohort study in Norway. The study concludes that use of SPF ≥ 15 sunscreen by all women age 40 to 75 years could potentially reduce their melanoma incidence by 18%.
A finding from a New Zealand study suggests that vitamin D status is increased by regular small sun exposures (<2 SEDEFB per week), and that greater exposures result in only small additional increases in 25(OH)D3.
While more advanced cutaneous head and neck melanomas (CHNM) were diagnosed on posterior compared with anterior locations, location was not a significant prognostic factor for cutaneous melanoma–specific or overall death in the multivariable models, according to findings of a recent study.
Response rates to PD-1 blockade in patients with acral and mucosal melanomas were comparable to the published rates in patients with cutaneous melanoma and support the routine use of PD-1 blockade in clinical practice, according to authors of a recently published study.